Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Aduro Biotech, Inc is a biotechnology business based in the US. Aduro Biotech shares (ADRO) are listed on the NASDAQ and all prices are listed in US Dollars. Aduro Biotech employs 69 staff and has a trailing 12-month revenue of around USD$28 million.
|52-week range||USD$4.9 - USD$20.2|
|50-day moving average||USD$3.71|
|200-day moving average||USD$2.9131|
|Wall St. target price||USD$18.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.15|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Aduro Biotech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Aduro Biotech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Aduro Biotech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.06. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Aduro Biotech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||USD$28 million|
|Gross profit TTM||USD$-48,610,000|
|Return on assets TTM||-13.9%|
|Return on equity TTM||-87.44%|
|Market capitalisation||USD$236.6 million|
TTM: trailing 12 months
There are currently 3.2 million Aduro Biotech shares held short by investors – that's known as Aduro Biotech's "short interest". This figure is 2.7% down from 3.3 million last month.
There are a few different ways that this level of interest in shorting Aduro Biotech shares can be evaluated.
Aduro Biotech's "short interest ratio" (SIR) is the quantity of Aduro Biotech shares currently shorted divided by the average quantity of Aduro Biotech shares traded daily (recently around 688870.17167382). Aduro Biotech's SIR currently stands at 4.66. In other words for every 100,000 Aduro Biotech shares traded daily on the market, roughly 4660 shares are currently held short.
However Aduro Biotech's short interest can also be evaluated against the total number of Aduro Biotech shares, or, against the total number of tradable Aduro Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aduro Biotech's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Aduro Biotech shares in existence, roughly 40 shares are currently held short) or 0.0486% of the tradable shares (for every 100,000 tradable Aduro Biotech shares, roughly 49 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aduro Biotech.
Find out more about how you can short Aduro Biotech stock.
We're not expecting Aduro Biotech to pay a dividend over the next 12 months.
Aduro Biotech's shares were split on a 1:5 basis on 2 October 2020. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aduro Biotech shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Aduro Biotech shares which in turn could have impacted Aduro Biotech's share price.
Over the last 12 months, Aduro Biotech's shares have ranged in value from as little as $4.9 up to $20.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aduro Biotech's is 0.3861. This would suggest that Aduro Biotech's shares are less volatile than average (for this exchange).
Aduro Biotech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation clinical trial and Phase Ib dose escalation clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase II clinical trial in combination with pembrolizumab, an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and natural killer cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B.V.; and license agreements with Karagen Pharmaceuticals, Inc., UC Berkeley, and Memorial Sloan Kettering Cancer Center. The company was formerly known as Oncologic, Inc. and changed its name to Aduro Biotech, Inc. in June 2008. Aduro Biotech, Inc. was founded in 2000 and is headquartered in Berkeley, California.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.